A mini‑review of the validity, quality and efficacy of candidate vaccines in controlling the COVID-۱۹

Few would have thought that in this century, a new coronavirus called SARS-CoV-۲ would kill many people around the world, cripple the economy, and leave the medical staff helpless. Severe acute respiratory syndrome coronavirus ۲ (SARS-CoV-۲), a virus that first appeared in Wuhan, China, and spread rapidly around the world, and strict quarantines did not prevent the severe prevalence from spreading worldwide. Antiviral drugs do not work well enough for everyone. The mortality rate in the world is still significant. The only thing that gives hope to the people of the world is the hope of being vaccinated, so by producing vaccines in the shortest possible time, science has once again saved humanity. Thus, from the very beginning, pharmaceutical companies started to produce safe vaccines. Currently, more than ۲۰۰ types of vaccines around the world are undergoing various stages of production, and about ۳۰ vaccines have entered the clinical trial phase, of which ۹ vaccines have entered phase ۱ to ۳ of clinical trials. DNA and RNA-based vaccines were first developed and were not licensed before coronavirus disease ۲۰۱۹ (COVID-۱۹). Other types of vaccines, including non-replicating viral vectors as well as inactivated vaccines, are undergoing clinical phases. There are currently ۹ common vaccines Inovio Pharmaceuticals, Moderna, BioNTech/Pfizer, AstraZeneca, CanSino Biological, Gam-COVID-Vac (Sputnik V), Wuhan Institute of Biological Products/Sinopharm, Beijing Institute of Biological Products/Sinopharm, and Sinovac Institutes in the world. Vaccination with the Pfizer vaccine, which is approved by the World Health Organization (WHO), is underway in many countries. The WHO predicts that by the end of ۲۰۲۱, one billion people worldwide will be vaccinated by the company.

Keywords:

SARS-CoV-۲ , COVID-۱۹ , Vaccine , Pfizer , Moderna , AstraZeneca